What Are Ascites in Cancer? Causes, Signs & Diagnosis

Ascites in cancer refers to an abnormal buildup of fluid inside the peritoneal cavity, the space between the abdominal organs and the abdominal wall. When that fluid contains malignant cells or results directly from tumor activity in the abdomen, clinicians call it malignant ascites. It is a serious complication that signals advanced disease, with average survival from diagnosis around 20 weeks, though the outlook varies widely depending on the type of cancer and how it responds to treatment.¹ The condition affects comfort, breathing, nutrition, and daily function, and understanding what drives it helps make sense of the treatment options available.

How Malignant Ascites Forms

Your peritoneal cavity normally contains a small amount of fluid that lubricates the organs as they move. The body constantly produces and reabsorbs this fluid, keeping the volume in check. In cancer, two overlapping problems disrupt that balance. First, tumor deposits on the peritoneal lining block the tiny lymphatic vessels that normally drain fluid out of the abdomen. When those drainage channels are obstructed, fluid accumulates with no exit route.² Second, the tumors themselves release signaling molecules, especially vascular endothelial growth factor (VEGF), that make blood vessels abnormally leaky. Protein-rich plasma seeps through vessel walls into the abdominal space, pulling even more water along with it.³ The combination of blocked drainage and increased vascular permeability means fluid pours in faster than it can leave, sometimes accumulating liters in a matter of days or weeks.

One clue that vascular leakiness is involved comes from the fluid itself. Malignant ascites tends to have a high protein concentration, sometimes close to what you would measure in blood serum, because the leaky vessels allow large proteins to pass through. That is distinct from some other causes of ascites, where the fluid is more watery and protein-poor.²

Which Cancers Cause It Most Often

Not every cancer causes ascites. The cancers most commonly associated with malignant ascites are adenocarcinomas of the ovary, breast, colon, stomach, and pancreas.⁴ These tend to be cancers that either originate in the abdomen or spread readily to the peritoneal surface. Ovarian cancer stands out because ascites is practically a hallmark of the disease, appearing in a large proportion of patients, often at initial presentation. The fluid in ovarian cancer ascites contains cellular and molecular components that actively help the cancer spread and resist chemotherapy, making it more than just a passive symptom.⁵

Gastrointestinal cancers, particularly those of the stomach, colon, and pancreas, cause ascites when they seed the peritoneal lining with metastatic deposits. Breast cancer can do the same, though less commonly. In a cohort study examining the causes of ascites in an unselected medical population, malignancy accounted for about 29% of all cases, second only to cirrhosis.⁶ That is a significant share, and it underscores why new-onset ascites in someone without known liver disease should always raise the question of cancer.

Signs and Symptoms to Watch For

Small volumes of ascites can be entirely silent. As the fluid increases, the most common early symptom is a feeling of fullness or bloating that does not go away with dietary changes. Your clothes may feel tighter around the waist even though your weight has not changed much on the scale, or conversely, you may notice unexplained weight gain without eating more.

As fluid continues to accumulate, symptoms escalate:

Abdominal distension: The belly visibly enlarges, sometimes dramatically over a few weeks.
Breathing difficulty: Large-volume ascites pushes the diaphragm upward, compressing the lungs. In severe cases, this causes frank respiratory distress.⁷
Loss of appetite and nausea: Pressure on the stomach and intestines limits how much you can eat and makes meals uncomfortable.
Swelling elsewhere: Loss of proteins into the ascitic fluid can cause widespread edema, particularly in the legs.⁸
Fatigue: The combination of poor nutrition, protein loss, and the effort of carrying extra fluid volume leaves patients exhausted.

Malignant ascites also increases susceptibility to infection. The protein- and cell-rich fluid in the abdomen can become a breeding ground for bacteria, and the electrolyte imbalances caused by ongoing fluid shifts further strain the body.⁸

How Ascites Is Detected on Examination and Imaging

Doctors have traditionally checked for ascites at the bedside using maneuvers like shifting dullness, where the area of dullness on percussion shifts when the patient rolls to one side, and the fluid wave test, where a tap on one side of the abdomen sends a visible ripple across to the other. These methods are intuitive but imperfect. One study found that shifting dullness and fluid wave had positive predictive values of only about 51% and 73%, respectively, meaning a substantial number of “positive” findings turned out to be false alarms.⁹ The physical exam works best when there is already a moderate to large amount of fluid present. Small-volume ascites is easily missed.

Ultrasound is the go-to imaging tool for confirming ascites. It is inexpensive, radiation-free, and can detect even small pockets of fluid that physical examination cannot. In a study comparing ultrasound with CT for evaluating intra-abdominal disease in ovarian cancer, ultrasound had slightly better sensitivity for detecting ascites.¹⁰ CT scans, meanwhile, provide a more comprehensive look at the entire abdomen and pelvis, revealing not just the fluid but also the tumor deposits, lymph node involvement, and organ changes that may be causing it. In practice, most patients with new ascites will get both: an ultrasound for quick confirmation and a CT scan for staging and planning.

Analyzing the Fluid Itself

Once imaging confirms ascites, the next step is usually a diagnostic paracentesis, a needle inserted through the abdominal wall to withdraw a sample of the fluid. The analysis of that fluid is what separates malignant ascites from the many other possible causes.

Cytology

The most direct test is cytology: a pathologist examines the fluid under a microscope looking for cancer cells. When those cells are found, the diagnosis is confirmed. The catch is that cytology misses a significant number of cases. In one study of ovarian clear cell carcinoma, the overall cytologic detection rate across all stages was 38%, with 54 out of 143 cases testing positive for malignancy. Ascites fluid performed better than pelvic wash specimens in early-stage disease, picking up cancer in 77% of stage 1 cases when ascites was present.¹¹ Still, a negative cytology does not rule out malignancy, and that gap has driven interest in supplementary tests.

Tumor Markers in the Fluid

Measuring tumor markers directly in the ascitic fluid, rather than just in blood, adds diagnostic power. Markers like CA125, CEA, and CA19-9 measured in ascites fluid are significantly associated with peritoneal carcinomatosis in both gastrointestinal and ovarian malignancies.¹² And these markers perform better when measured in the fluid than in the blood. In cases where cytology comes back negative but cancer is still suspected, combining ascitic tumor markers yielded 86% sensitivity and 97% specificity for distinguishing malignant from benign ascites, and adding tumor markers to cytology increased the diagnostic yield by about 37%.¹³

A systematic review confirmed this pattern: CEA showed high diagnostic performance when measured in ascitic fluid, and inflammatory markers like CRP, IL-6, and VEGF added value when cytology was inconclusive. Using marker ratios, specifically comparing the ascitic level to the serum level, further improved reliability.¹⁴

Distinguishing Cancer-Related Ascites from Other Causes

Cancer is not the only thing that causes fluid to build up in the abdomen. Liver cirrhosis is the most common cause overall, responsible for roughly 55% of cases in one cohort, followed by malignancy at about 29% and heart failure at about 6%.⁶ Differentiating between these causes matters because the treatment approaches are fundamentally different.

The serum-ascites albumin gradient, or SAAG, is the standard first-pass test. It works by comparing the albumin level in the blood to the albumin level in the ascitic fluid. A high gradient (1.1 g/dL or more) suggests the ascites is driven by portal hypertension, most often from cirrhosis. A low gradient points toward other causes, including cancer. In one study, a SAAG at or above 11 g/L had a sensitivity of about 86% and specificity of about 61% for identifying portal hypertension as the cause.⁶

The SAAG is a useful starting point, but it is not infallible. Some patients have “mixed ascites,” meaning they have both liver disease and cancer contributing simultaneously. In those situations, SAAG can be misleading. Measuring ascitic cholesterol levels has emerged as a complementary approach. At a cutoff of 45 mg/dL, ascitic cholesterol was superior to SAAG in identifying non-portal-hypertension-related ascites, and in patients whom SAAG misclassified, ascitic cholesterol correctly reclassified about 69% of them.¹⁵ This is particularly relevant for cancer patients who also happen to have underlying liver disease, a population where the diagnostic overlap creates real clinical uncertainty.

Managing the Fluid Buildup

The definitive treatment for malignant ascites is treating the cancer itself. If chemotherapy or targeted therapy can shrink the peritoneal disease, fluid production slows or stops. But when the underlying cancer is refractory to treatment, or while waiting for systemic therapy to take effect, the focus shifts to palliation, relieving the physical burden of the fluid.

The most common intervention is large-volume paracentesis, where a needle and catheter are inserted through the abdominal wall and several liters of fluid are drained in one session. It provides rapid relief but is temporary; the fluid almost always comes back, sometimes within days. Patients who need frequent paracentesis end up making repeated trips to the hospital, which takes a toll on quality of life.

For patients who accumulate fluid rapidly, indwelling peritoneal catheters offer an alternative. These tunneled catheters stay in place permanently and allow drainage at home, eliminating the need for repeated hospital visits. One study found that a permanent peritoneal catheter was a valuable method for reducing symptom burden and was easy to use at home, with an acceptable complication rate that was balanced by the benefits of avoiding frequent paracentesis.¹⁶ A comparison of Pleurx-type catheters with standard large-volume paracentesis found similar complication rates but noted the catheter approach eliminated the need for frequent hospital trips for drainage.¹⁷

Peritoneovenous shunts, which route ascitic fluid from the abdomen back into the venous bloodstream, are another option but carry the most serious complication risk of any drainage method.¹⁸ They are generally reserved for patients who have failed other approaches and whose fluid does not contain high levels of blood or debris that could cause clotting problems.

Targeting the Root Cause with VEGF Inhibition

Because VEGF plays such a central role in making blood vessels leaky and driving fluid accumulation, researchers have explored whether blocking VEGF could shut off ascites production at its source. Bevacizumab, an anti-VEGF antibody already used intravenously for several cancers, has been tested as a direct intraperitoneal injection for refractory malignant ascites. In one small series of nine patients with ascites from colorectal, breast, uterine, or ovarian cancer, the malignant ascites resolved after a single intraperitoneal dose in every patient treated. No reaccumulation or repeat paracentesis was needed over a median follow-up of more than two months, and no serious adverse events occurred.¹⁹ That is a striking result for a nine-patient series, but it remains preliminary. The approach makes biological sense given the known role of VEGF, and larger trials are needed to confirm whether the results hold up across broader patient populations.²⁰

The Impact on Muscle and Nutritional Status

Malignant ascites does not just cause discomfort. It accelerates the systemic decline that cancer patients often experience. A study of advanced-stage ovarian cancer patients found that those with ascites lost significantly more muscle mass after treatment compared with those without ascites. Muscle index dropped by about 4% in the ascites group while actually increasing by about 2% in patients without it. Markers of systemic inflammation were correspondingly worse: albumin levels fell more steeply, and inflammatory ratios worsened substantially in patients with ascites.²¹

This matters practically because muscle loss and poor nutritional status make it harder for patients to tolerate chemotherapy, recover from surgery, and maintain independence. The fluid itself contains proteins and immune cells that the body cannot easily replace, creating a vicious cycle: the cancer drives fluid production, the fluid drains the body of resources, and the weakened body is less able to fight the cancer or tolerate treatment. Addressing nutrition early and draining fluid when it reaches symptomatic levels are not just about comfort; they affect the patient’s ability to continue cancer treatment.

Prognosis and What Influences It

The development of malignant ascites generally signals advanced disease, and the prognosis is sobering. Average survival from the time of diagnosis is about 20 weeks, though there is wide variation depending on cancer type, stage, and response to treatment.¹ In one study from a major hospital, only about 32% of patients with malignant ascites were still alive after six months. Factors that predicted worse outcomes included having the primary cancer already at an advanced stage at diagnosis and elevated serum creatinine levels, suggesting kidney strain.²²

Ovarian cancer is something of an exception here. Because ovarian cancer often responds to platinum-based chemotherapy, even patients who present with significant ascites may see the fluid resolve with treatment and go on to have meaningful periods of disease control. The prognosis of malignant ascites depends heavily on the underlying tumor biology, and blanket survival statistics can be misleading when applied to any individual patient.

Emerging Diagnostic Tools

Researchers are exploring whether the ascitic fluid itself can yield more than just a yes-or-no answer about cancer. Cell-free tumor DNA, fragments of DNA shed by cancer cells, can be detected in peritoneal fluid. In a study of patients with peritoneal carcinomatosis, KRAS mutant DNA was found in 40% of peritoneal fluid samples. Among patients with detectable cell-free tumor DNA, the concentration of that DNA appeared to correlate with whether the disease was resectable: about 71% of patients whose tumors could still be surgically removed had low DNA concentrations (less than 1% mutant allele fraction), while 75% of those with unresectable disease had higher concentrations.²³ If validated in larger studies, this kind of test could help clinicians decide which patients are good candidates for aggressive surgical approaches and which would be better served by systemic therapy alone.

On the treatment side, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a technique that delivers chemotherapy as a fine mist directly into the abdominal cavity during a minimally invasive procedure. A registry study found that ascites diminished significantly in patients who underwent PIPAC.²⁴ The approach is still relatively new and not widely available, but it represents a growing interest in treating peritoneal disease directly rather than relying solely on intravenous chemotherapy to reach the abdominal cavity from the bloodstream.

1
PubMed Central. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures
2
ScienceDirect. Anti-tumour Treatment Malignant ascites: Current therapy options and treatment prospects
3
PubMed. Vascular permeability factor (VPF, VEGF) in tumor biology
4
PubMed Central. Management of ascites due to gastrointestinal malignancy
5
PubMed Central. The untapped potential of ascites in ovarian cancer research and treatment
6
PubMed Central. Diagnostic accuracy of serum ascites albumin gradient (SAAG) in a contemporary unselected medical cohort
7
PubMed Central. Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy
8
PubMed. Malignant ascites: pathophysiology and treatment
9
PubMed Central. The predictive value of physical examinations for ascites
10
International Journal of Gynecological Cancer. Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography
11
PubMed. The diagnostic accuracy and prognostic implication of pelvic and peritoneal fluid cytology specimens in ovarian clear cell carcinoma
12
PubMed Central. CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies
13
PubMed. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites
14
PubMed Central. The Diagnostic Role of Tumor and Inflammatory Biomarkers in Ascitic Fluid: A Systematic Review
15
PubMed. Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites and the diagnosis of mixed ascites
16
PubMed. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients
17
PubMed. Comparison of percutaneous management techniques for recurrent malignant ascites
18
PubMed Central. Drainage of malignant ascites: patient selection and perspectives
19
The Oncologist. Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
20
PubMed. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
21
PubMed Central. Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer
22
Myanmar Health Sciences Research Journal. Parameters Predicting Poor Prognosis in Patients with Malignant Ascites in Yangon General Hospital
23
PubMed Central. Peritoneal cell-free tumor DNA as biomarker for peritoneal surface malignancies
24
PubMed Central. Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study